Journal of Clinical Oncology
Articles in this Issue
Building a patient-driven, integrated research infrastructure to accelerate therapeutic advances in colorectal cancer.
e15615 Background: Despite major scientific advances, colorectal cancer (CRC) remains a leading cause of cancer-related mo...
Role of VISTA/TIM3 heterodimerization and macrophage metabolic reprogramming in microsatellite stable colorectal cancer.
e15586 Background: Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibodies, represent a major paradigm shif...
A phase II clinical trial of intravesical YH01 for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC).
e16612 Background: Non–muscle-invasive bladder cancer (NMIBC) accounts for approximately 70–80% of bladder cancer cases. N...
Multi-exposure environmental mapping and scale effects in lung cancer risk assessment: An ecological synthesis from central Argentina.
e22582 Background: Lung cancer is a major public health burden and, beyond tobacco smoking, its risk may be influenced by...
Phase 1 faecal microbiota transplantation in patients with advanced pancreatic carcinoma (FMTPanc Trial).
TPS4262 Background: Higher abundance of specific oral, pancreatic and/or gut microbes is correlated with pancreatic cancer...
Inpatient financial toxicity among women hospitalized with breast cancer in the United States, 2013–2022.
1555 Background: Financial toxicity is an increasingly recognized consequence of cancer care. While the outpatient costs o...
Disaggregated lung cancer mortality trends in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) patients by key sociodemographic features including sex, age, and smoking status.
8593 Background: Lung cancer is a leading cause of death in AANHPI populations, yet studies aggregate patients with divers...
Wire-guided versus radio-guided localization for non-palpable occult lesion in breast tissue: A systematic review and meta-analysis.
579 Background: Accurate preoperative localization of non-palpable breast lesions is crucial for successful breast-conserv...
Epidemiologic trends and risk factor transitions in adolescent and young adult lung cancer in East Asia, 1990–2023.
e22587 Background: East Asia bears the highest global burden of adolescent and young adult (AYA) lung cancer. Updated regi...
More than follow-up: Outcomes from an integrated cancer survivorship wellness clinic.
e13796 Background: Studies have identified persistent gaps in survivorship care coordination, particularly fragmented comm...
Metastatic pancreatic cancer in elderly patients.
e16347 Background: Elderly patients are underrepresented in clinical trials, and real-world data on treatment patterns and...
A phase II study evaluating treatment discontinuation of dual anti-HER2 therapy in metastatic HER2-positive breast cancer after five years of sustained complete response (FREEDOME-trial).
TPS1143 Background: Dual anti-HER2 therapy with trastuzumab (T) and pertuzumab (P) has transformed outcomes in HER2-positi...
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
5503 Background: Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist that increases tumor sensi...
Screening and trends: A Global Burden of Disease 2023 assessment of colorectal cancer mortality across G7 nations.
3656 Background: Historically, the adoption of screening techniques has led to a steady decline in colorectal carcinoma (C...
Disease kinetics and practice patterns in ≥ 4-year long-term beneficiaries of immune checkpoint inhibitors for advanced non–small cell lung cancer.
8561 Background: Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced non-small cell lung cancer (NSC...
Prognostic significance and healthcare resource utilization of emergency department visit etiology in patients with prostate cancer.
e23178 Background: Patients with prostate cancer (PC) frequently present to the emergency department (ED), yet the underly...
Baseline peripheral blood activated-to-total CD8⁺ central memory T cell ratio to identify melanoma patients at high risk for severe toxicity but limited clinical benefit.
2568 Background: Immune-related adverse events (irAEs) represent a major clinical challenge that limits the usage of immun...
Opioid prescribing in cancer patients compared with non-cancer patients over two decades (2000-2021) among a national veterans population.
e23347 Background: Evaluating trends in opioid prescribing for veterans with cancer is essential for understanding the imp...
Transforming evidence into answers: An agentic framework to support living clinical practice guidelines.
e17004 Background: Living clinical practice guidelines offer the opportunity to keep recommendations aligned with the late...
Characterizing molecular and clinical features of systemic cancers that spread to the intradural spine.
e14042 Background: Metastatic cancers to the central nervous system (CNS) usually affect the brain. A small but clinically...
Rethinking MRI surveillance after breast cancer in the context of persistent racial disparities in mortality.
1675 Background: Detection of asymptomatic breast cancer recurrence by imaging is associated with improved survival compar...
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with <i>BRAF</i> V600E-mutant metastatic colorectal cancer.
3559 Background: While the doublet combination of encorafenib (ENCO) + cetuximab (CET) is a standard treatment for patient...
Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.
7046 Background: Cohort 1 of the phase 3 SEQUOIA trial assessed zanu, a next-generation BTKi, compared to BR in TN CLL/SLL...
Dynamic remodeling of the extracellular vesicle proteome during systemic therapy in advanced non–small cell lung cancer.
e15059 Background: Non–small cell lung cancer (NSCLC) remains associated with poor prognosis in advanced stages, and relia...
Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)–naive patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
6566 Background: In the phase 3 COMMANDS trial (NCT03682536), luspatercept (LUSPA) significantly improved RBC-TI ≥12 wks w...